Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the approval of the drug on Thursday.

Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say it shouldn't be approved.

A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling. The European Medicines Agency committee said the benefits of the new drug,